<?xml version="1.0" encoding="UTF-8"?>
<p>It is also noteworthy that prior use of HIV PrEP was the variable most strongly associated with willingness to use syphilis PrEP in our multivariable model. This finding is encouraging, given the high incidence of STIs in HIV PrEP users,
 <sup>
  <xref rid="bib23" ref-type="bibr">23</xref>
 </sup> and ongoing concern about the potential for HIV PrEP to contribute to these epidemics. Members of our team are currently conducting an exploratory trial of combined syphilis and HIV PrEP using both daily doxycycline and tenofovir disoproxil fumarate/emtricitabine, with final results expected in summer/fall 2020.
 <sup>
  <xref rid="bib24" ref-type="bibr">24</xref>
 </sup>
</p>
